目的 探讨班布特罗联合莫西沙星治疗慢性阻塞性肺疾病急性加重期的临床疗效。方法 选取2012年1月-2016年1月在乌鲁木齐市友谊医院治疗的慢性阻塞性肺疾病急性加重期患者88例，随机分为对照组和治疗组，每组各44例。对照组睡前口服盐酸莫西沙星片，0.4 mg/次，1次/d；治疗组在对照组的基础上睡前口服盐酸班布特罗片，10 mg/次，1次/d。两组患者均连续治疗8 d。观察两组临床疗效，比较两组患者的白细胞计数（WBC）、中性粒细胞（NBC）和C反应蛋白（CRP）以及血气指标变化情况。结果 治疗后，对照组和治疗组患者的总有效率分别为77.3%、90.9%，两组总有效率比较差异有统计学意义（P<0.05）。治疗后，两组患者的WBC、NBC和CRP均较治疗前显著下降，同组治疗前后差异具有统计学意义（P<0.05）；且治疗组上述指标的改善程度优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者血氧分压（pO₂）较治疗前显著升高，而二氧化碳分压（pCO₂）较治疗前显著降低，同组比较差异具有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 班布特罗联合莫西沙星治疗慢性阻塞性肺疾病急性加重期具有良好的临床疗效，可以降低患者的气道阻力，有效控制肺部感染，缓解患者的呼吸困难，改善患者的肺功能，具有一定的临床推广应用价值。

Objective To evaluate the clinical efficacies of bambuterol combined with moxifloxacin in treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods Patients (88 cases) with acute exacerbation of chronic obstructive pulmonary disease in Urumqi Friendship Hospital from January 2012 to January 2016 were randomly divided into control and treatment groups, and each group had 44 cases. The patients in the control group were po administered with Moxifloxacin Hydrochloride Tablets before sleeping, 0.4 mg/time, once daily. The patients in the treatment group were po administered with Bambuterol Hydrochloride Tablets before sleeping on the basis of the control group, 10 mg/time, once daily. The patients in two groups were treated for 8 d. After treatment, the efficacy was evaluated, and WBC, NBC, and CRP, and blood gas indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 77.3% and 90.9%, respectively, and there was difference between two groups (P<0.05). After treatment, WBC, CRP, and NBC in two groups were significantly decreased, and the differences were statistically significant in the same group (P<0.05). And the improvement of the observational indexes in the treatment group was significantly better than those in the control group, with significant differences between two groups (P<0.05). After treatment, pO₂ in two groups was significantly increased, but the pCO₂ was decreased, and the differences were statistically significant in the same group (P<0.05). And these observational indexes in the treatment group were significantly better than those in the control group, with significant differences between two groups (P<0.05). Conclusion s Bambuterol combined with moxifloxacin has a good clinical efficacy in treatment of acute exacerbation of chronic obstructive pulmonary disease, can reduce airway resistance with effective controlling of pulmonary infection, dyspnea relieving, and improvement of pulmonary function, which has a certain clinical application value.